Research ArticleSpecial Issue on Drug Delivery Technologies
In Vivo Imaging of Small Molecular Weight Peptides for Targeted Renal Drug Delivery: A Study in Normal and Polycystic Kidney Diseased Mice
Stephen C. Lenhard, Allen McAlexander, Anthony Virtue, William Fieles, Tina Skedzielewski, Mary Rambo, Han Trinh, Shih-Hsun Cheng, Hyundae Hong, Albert Isidro-Llobet, Alan Nadin, Robert Geske, Jean-Louis Klein, Dennis Lee, Beat M. Jucker and Erding Hu
Journal of Pharmacology and Experimental Therapeutics September 2019, 370 (3) 786-795; DOI: https://doi.org/10.1124/jpet.119.257022
Stephen C. Lenhard
Bioimaging (S.C.L., T.S., M.R., S.-H.C., H.H., B.M.J.), Renal Discovery Group, Future Pipeline Discovery (A.V, E.H.), Experimental Cell and Tissue Biology, Target and Pathway Validation (W.F., H.T., R.G., J.-L.K.), Drug Delivery (A.M., D.L.), and Drug Design and Selection (A.I.-L., A.N.), GlaxoSmithKline plc, Collegeville, Pennsylvania
Allen McAlexander
Bioimaging (S.C.L., T.S., M.R., S.-H.C., H.H., B.M.J.), Renal Discovery Group, Future Pipeline Discovery (A.V, E.H.), Experimental Cell and Tissue Biology, Target and Pathway Validation (W.F., H.T., R.G., J.-L.K.), Drug Delivery (A.M., D.L.), and Drug Design and Selection (A.I.-L., A.N.), GlaxoSmithKline plc, Collegeville, Pennsylvania
Anthony Virtue
Bioimaging (S.C.L., T.S., M.R., S.-H.C., H.H., B.M.J.), Renal Discovery Group, Future Pipeline Discovery (A.V, E.H.), Experimental Cell and Tissue Biology, Target and Pathway Validation (W.F., H.T., R.G., J.-L.K.), Drug Delivery (A.M., D.L.), and Drug Design and Selection (A.I.-L., A.N.), GlaxoSmithKline plc, Collegeville, Pennsylvania
William Fieles
Bioimaging (S.C.L., T.S., M.R., S.-H.C., H.H., B.M.J.), Renal Discovery Group, Future Pipeline Discovery (A.V, E.H.), Experimental Cell and Tissue Biology, Target and Pathway Validation (W.F., H.T., R.G., J.-L.K.), Drug Delivery (A.M., D.L.), and Drug Design and Selection (A.I.-L., A.N.), GlaxoSmithKline plc, Collegeville, Pennsylvania
Tina Skedzielewski
Bioimaging (S.C.L., T.S., M.R., S.-H.C., H.H., B.M.J.), Renal Discovery Group, Future Pipeline Discovery (A.V, E.H.), Experimental Cell and Tissue Biology, Target and Pathway Validation (W.F., H.T., R.G., J.-L.K.), Drug Delivery (A.M., D.L.), and Drug Design and Selection (A.I.-L., A.N.), GlaxoSmithKline plc, Collegeville, Pennsylvania
Mary Rambo
Bioimaging (S.C.L., T.S., M.R., S.-H.C., H.H., B.M.J.), Renal Discovery Group, Future Pipeline Discovery (A.V, E.H.), Experimental Cell and Tissue Biology, Target and Pathway Validation (W.F., H.T., R.G., J.-L.K.), Drug Delivery (A.M., D.L.), and Drug Design and Selection (A.I.-L., A.N.), GlaxoSmithKline plc, Collegeville, Pennsylvania
Han Trinh
Bioimaging (S.C.L., T.S., M.R., S.-H.C., H.H., B.M.J.), Renal Discovery Group, Future Pipeline Discovery (A.V, E.H.), Experimental Cell and Tissue Biology, Target and Pathway Validation (W.F., H.T., R.G., J.-L.K.), Drug Delivery (A.M., D.L.), and Drug Design and Selection (A.I.-L., A.N.), GlaxoSmithKline plc, Collegeville, Pennsylvania
Shih-Hsun Cheng
Bioimaging (S.C.L., T.S., M.R., S.-H.C., H.H., B.M.J.), Renal Discovery Group, Future Pipeline Discovery (A.V, E.H.), Experimental Cell and Tissue Biology, Target and Pathway Validation (W.F., H.T., R.G., J.-L.K.), Drug Delivery (A.M., D.L.), and Drug Design and Selection (A.I.-L., A.N.), GlaxoSmithKline plc, Collegeville, Pennsylvania
Hyundae Hong
Bioimaging (S.C.L., T.S., M.R., S.-H.C., H.H., B.M.J.), Renal Discovery Group, Future Pipeline Discovery (A.V, E.H.), Experimental Cell and Tissue Biology, Target and Pathway Validation (W.F., H.T., R.G., J.-L.K.), Drug Delivery (A.M., D.L.), and Drug Design and Selection (A.I.-L., A.N.), GlaxoSmithKline plc, Collegeville, Pennsylvania
Albert Isidro-Llobet
Bioimaging (S.C.L., T.S., M.R., S.-H.C., H.H., B.M.J.), Renal Discovery Group, Future Pipeline Discovery (A.V, E.H.), Experimental Cell and Tissue Biology, Target and Pathway Validation (W.F., H.T., R.G., J.-L.K.), Drug Delivery (A.M., D.L.), and Drug Design and Selection (A.I.-L., A.N.), GlaxoSmithKline plc, Collegeville, Pennsylvania
Alan Nadin
Bioimaging (S.C.L., T.S., M.R., S.-H.C., H.H., B.M.J.), Renal Discovery Group, Future Pipeline Discovery (A.V, E.H.), Experimental Cell and Tissue Biology, Target and Pathway Validation (W.F., H.T., R.G., J.-L.K.), Drug Delivery (A.M., D.L.), and Drug Design and Selection (A.I.-L., A.N.), GlaxoSmithKline plc, Collegeville, Pennsylvania
Robert Geske
Bioimaging (S.C.L., T.S., M.R., S.-H.C., H.H., B.M.J.), Renal Discovery Group, Future Pipeline Discovery (A.V, E.H.), Experimental Cell and Tissue Biology, Target and Pathway Validation (W.F., H.T., R.G., J.-L.K.), Drug Delivery (A.M., D.L.), and Drug Design and Selection (A.I.-L., A.N.), GlaxoSmithKline plc, Collegeville, Pennsylvania
Jean-Louis Klein
Bioimaging (S.C.L., T.S., M.R., S.-H.C., H.H., B.M.J.), Renal Discovery Group, Future Pipeline Discovery (A.V, E.H.), Experimental Cell and Tissue Biology, Target and Pathway Validation (W.F., H.T., R.G., J.-L.K.), Drug Delivery (A.M., D.L.), and Drug Design and Selection (A.I.-L., A.N.), GlaxoSmithKline plc, Collegeville, Pennsylvania
Dennis Lee
Bioimaging (S.C.L., T.S., M.R., S.-H.C., H.H., B.M.J.), Renal Discovery Group, Future Pipeline Discovery (A.V, E.H.), Experimental Cell and Tissue Biology, Target and Pathway Validation (W.F., H.T., R.G., J.-L.K.), Drug Delivery (A.M., D.L.), and Drug Design and Selection (A.I.-L., A.N.), GlaxoSmithKline plc, Collegeville, Pennsylvania
Beat M. Jucker
Bioimaging (S.C.L., T.S., M.R., S.-H.C., H.H., B.M.J.), Renal Discovery Group, Future Pipeline Discovery (A.V, E.H.), Experimental Cell and Tissue Biology, Target and Pathway Validation (W.F., H.T., R.G., J.-L.K.), Drug Delivery (A.M., D.L.), and Drug Design and Selection (A.I.-L., A.N.), GlaxoSmithKline plc, Collegeville, Pennsylvania
Erding Hu
Bioimaging (S.C.L., T.S., M.R., S.-H.C., H.H., B.M.J.), Renal Discovery Group, Future Pipeline Discovery (A.V, E.H.), Experimental Cell and Tissue Biology, Target and Pathway Validation (W.F., H.T., R.G., J.-L.K.), Drug Delivery (A.M., D.L.), and Drug Design and Selection (A.I.-L., A.N.), GlaxoSmithKline plc, Collegeville, Pennsylvania
Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Research ArticleSpecial Issue on Drug Delivery Technologies
Renal Targeting in Normal and Polycystic Kidney Disease Mice
Stephen C. Lenhard, Allen McAlexander, Anthony Virtue, William Fieles, Tina Skedzielewski, Mary Rambo, Han Trinh, Shih-Hsun Cheng, Hyundae Hong, Albert Isidro-Llobet, Alan Nadin, Robert Geske, Jean-Louis Klein, Dennis Lee, Beat M. Jucker and Erding Hu
Journal of Pharmacology and Experimental Therapeutics September 1, 2019, 370 (3) 786-795; DOI: https://doi.org/10.1124/jpet.119.257022
Research ArticleSpecial Issue on Drug Delivery Technologies
Renal Targeting in Normal and Polycystic Kidney Disease Mice
Stephen C. Lenhard, Allen McAlexander, Anthony Virtue, William Fieles, Tina Skedzielewski, Mary Rambo, Han Trinh, Shih-Hsun Cheng, Hyundae Hong, Albert Isidro-Llobet, Alan Nadin, Robert Geske, Jean-Louis Klein, Dennis Lee, Beat M. Jucker and Erding Hu
Journal of Pharmacology and Experimental Therapeutics September 1, 2019, 370 (3) 786-795; DOI: https://doi.org/10.1124/jpet.119.257022
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement